Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
33 Results for "
Costic acid
" in MedChemExpress (MCE) Product Catalog:
Products (33)
33 Results for "Costic acid" in MCE Product Catalog:
Target:
Cat. No.: HY-N16388
CAS No.: 28399-17-9
Cat. No.: HY-N3494
CAS No.: 69978-82-1
Synonyms: IsoCostic acid
Target:
45
45 Publications Verification
Cat. No.: HY-D0819
CAS No.: 146368-14-1
Synonyms: Cy5 NHS Ester; Sulfo-Cyanine5 Succinimidyl Ester
45
45 Publications Verification
Cat. No.: HY-D0819A
CAS No.: 1497420-70-8
Synonyms: Cy5 NHS Ester triethylamine salt; Sulfo-Cyanine5 Succinimidyl Ester triethylamine salt
1
1
1 Cited Publications
Target:
Research Areas:
BTX161, a Thalidomide (HY-14658) analog, is a molecular glue degrader targeting CK1α. BTX161 recruits CK1α and the CK1α-FAM83 complex to the Cul4ACRBN E3 ligase complex, thereby driving ubiquitination and proteasomal degradation. BTX161 reduces FAM83G abundance through CK1α-FAM83G co-stability, slightly decreases FAM83H levels, but has no effect on the expression of FAM83B. BTX161 activates DNA damage response (DDR) and upregulates Wnt target genes including MYC. BTX161 can be used in research related to colorectal cancer, type b myelomonocytic leukemia and acute myeloid leukemia .
Cat. No.: HY-W127329
CAS No.: 106-14-9
Target:
Research Areas:
12-Hydroxystearic acid is a structurally simple and cost-effective low molecular weight organogelator, and its metal salts and derivatives find roles in many important applications .
Cat. No.: HY-116954
CAS No.: 21087-64-9
Target:
Research Areas:
Metribuzin is a low-cost non-selective herbicide belonging to the chemical class of triazinones. Metribuzin inhibits plant DNA synthesis and acts on photosystem II, ultimately suppressing photosynthesis. Metribuzin provides excellent control of important annual grass and broadleaf weeds .
Cat. No.: HY-W392173
CAS No.: 110615-47-9
Cat. No.: HY-DY1063
CAS No.: 146368-14-1
Solvent and concentration: DMSO: 10 mM
Cat. No.: HY-116954R
CAS No.: 21087-64-9
Target:
Research Areas:
Metribuzin (Standard) is the analytical standard of Metribuzin. This product is intended for research and analytical applications. Metribuzin is a low-cost non-selective herbicide that belongs to the chemical class of triazinones. Metribuzin hinders DNA synthesis in treated plants and acts on photosystem II, ultimately inhibiting photosynthesis. Metribuzin provides good control of important annual grass and broad-leaf weeds .
Cat. No.: HY-W592622
CAS No.: 25014-41-9
Target:
Research Areas:
Polyacrylonitrile (MW 250000) is a semicrystalline organic polymer resin, which exhibits high tensile strength, thermal stability, as well as resistance to chemical corrosion and sunlight . Polyacrylonitrile serves as a low-cost carrier material with stable chemical and mechanical properties for immobilizing laccase, and it can also be used to prepare nanofibers, membrane air filters, carbon fibers and water filters .
Cat. No.: HY-N10519
CAS No.: 120434-20-0
Target:
Cat. No.: HY-W127329R
CAS No.: 106-14-9
Category:
Target:
Cat. No.: HY-L099
2,294 compounds
MCE Targeted Diversity Library contains 2,294 compounds, covering more than 1000 targets and isoforms, such as GPCRs, Ion channel, variety of kinases, etc. 1-3 compounds with high potency and selectivity were carefully selected for each target and isoform. The bioactivity information of each compound has been clearly reported in the literatures. This library is a concise collection of small molecule compounds with comprehensive target coverage, which can be used for phenotypic screening at low cost.
Cat. No.: HY-L026
2,564 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.
MCE owns a unique collection of 2,564 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.
Cat. No.: HY-L035
5,147 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE Drug Repurposing Compound Library contains 5,147 approved drugs and passed phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.
Cat. No.: HY-L022M
3,237 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,237 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.
Cat. No.: HY-L022
3,237 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,237 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
